Results 141 to 150 of about 5,507 (191)
A Case of Acute Migraine Without Aura Treated With a New FDA-Approved Medication Ubrogepant. [PDF]
CureusShamsi MA, Khalid MA.
europepmc +1 more source
Opportunities for and Challenges of Pulmonary Drug Delivery in the Management of Acute Exacerbations of CNS Disorders. [PDF]
CNS DrugsDetyniecki K +5 more
europepmc +1 more source
Ergot alkaloid control in biotechnological processes and pharmaceuticals (a mini review). [PDF]
Front ToxicolVolnin A +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Outpatient Repetitive Intravenous Dihydroergotamine
Headache: The Journal of Head and Face Pain, 1992SYNOPSIS The efficacy of the repetitive intravenous dihydroergotamine (DHE) inpatient protocol for refractory headache is wellestablished. We conducted a retrospective and prospective study of long‐term headache patients at our clinic toevaluate this regimen in an outpatient setting.
L, Robbins, A, Remmes
openaire +2 more sources
Antidiarrheal Effects of Dihydroergotamine
The Journal of Clinical Pharmacology, 1977Dihydroergotamine (DHE), an alpha-adrenergic blocking agent, rapidly improved 121 out of 123 diarrheal patients. A hypotonic sigmoid and a hyperreactive rectum were found in these patients. Manometric studies of the distal colon showed that DHE counteracts the rectal hyperactivity and increases sigmoidal tone.
F, Lechin +3 more
openaire +2 more sources
Dihydroergotamine in postoperative ileus
Clinical Pharmacology and Therapeutics, 1983The effects of dihydroergotamine (DHE) on postoperative ileus after major abdominal surgery were studied. Forty-one patients received 0.5 mg DHE subcutaneously twice a day from the day of surgery to the seventh postoperative day. Thirty-three patients served as controls.
J, Thorup +3 more
openaire +2 more sources